Clinical Trials Browser

INDUSTRY × Has results × L-BLP25 × Clear all

NCT01496131 2018-03-09

Tecemotide (L-BLP25) in Prostate Cancer

Phase 2 Completed

28 enrolled 9 charts

Prostatic Neoplasms

NCT02049151 2017-08-23

START2

Phase 3 Terminated

35 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT01507103 2017-01-13

SPRINT

Phase 2 Completed

124 enrolled 9 charts

Gastrointestinal

Carcinoma, Neoplasms, Neoplasms by Site, Rectal Neoplasms

NCT01015443 2016-10-26

INSPIRE

Phase 3 Terminated

285 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT01423760 2016-10-06

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Phase NA Terminated

27 enrolled 7 charts

Plasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma

NCT01094548 2016-02-22

Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy

Phase 2 Completed

34 enrolled 12 charts

Multiple Myeloma

NCT00409188 2015-11-20

START

Phase 3 Completed

1,513 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00157209 2015-11-18

Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)

Phase 2 Completed

171 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00960115 2015-10-21

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Phase 1/2 Completed

178 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT00157196 2015-08-18

Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

Phase 2 Completed

22 enrolled 6 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00925548 2014-07-24

STRIDE

Phase 3 Terminated

16 enrolled 6 charts

Breast Neoplasms, Recurrence